This 11th edition of Cancer Management: A Multidisciplinary Approach reflects the ongoing commitment of the authors, editors, and publishers to rapidly disseminate to oncologists the most current information on the clinical management of cancer patients. The concept for this multidisciplinary text arose more than 10 years ago. We have since made every effort to update, refine, and optimize each new edition to meet the growing and changing needs of the more than 10,000 clinicians and cancer specialists who receive this publication each year, many of whom have told us they refer to this publication daily in their clinical practice.
Important updates and comprehensive revisions have been made to this latest 11th edition. Substantial changes have been made to a number of chapters, including those on breast cancer, non–small-cell lung cancer, colon, rectal, and anal cancers, and melanoma. Plus we’ve added a new color atlas on dermatologic toxicities associated with novel targeted therapies. And throughout the book, updates have been made to all of the chapters to reflect the latest information about cancer treatment and data on novel therapies and new and ongoing clinical trials.
This 11th volume also provides information on some of the oncology drugs that are listed below, which are newly approved or have received approval for a new indication since the last edition was published. These include: bendamustine (Treanda); bevacizumab(Drug information on bevacizumab) (Avastin); bortezomib(Drug information on bortezomib) (Velcade); dalteparin (Fragmin): denileukin diftitox (Ontak); dexrazoxane (Totect); docetaxel (Taxotere); doxorubicin(Drug information on doxorubicin) HCl liposome injection (Doxil); fosaprepitant dimeglumine for Injection (Emend); granisetron(Drug information on granisetron) (Sancuso); human papillomavirus (HPV) vaccine (Gardasil); ixabepilone (Ixempra); nilotinib(Drug information on nilotinib) (Tasigna); oxymorphone HCl (Opana); pemetrexed(Drug information on pemetrexed) (Alimta); romiplostim (Nplate); raloxifene(Drug information on raloxifene) hydrochloride (Evista); sorafenib(Drug information on sorafenib) (Nexavar); temsirolimus (Torisel); and topotecan(Drug information on topotecan) (Hycamtin): The 46 chapters and 4 Appendices in this newest edition represent the efforts of over 100 contributors from approximately 50 institutions in the United States and Canada.
Three consistent goals continue to guide our editorial policies:
- To provide practical information for physicians who manage cancer patients
- To present this information concisely, uniformly, and logically, emphasizing the natural history of the malignancy, screening and diagnosis, staging and prognosis, and treatment
- To emphasize a collaborative multidisciplinary approach to patient management that involves surgical, radiation, and medical oncologists, as well as other health care professionals, working as a cohesive team.
As with all previous editions, each chapter (as appropriate) in the current volume has been authored jointly by practicing medical, surgical, and radiation oncologists. In some cases, other specialists have been asked to contribute their expertise to a particular chapter.
All of our contributors personally manage patients using a multidisciplinary approach in their respective institutions. Thus, these chapters reflect the recommendations of practitioners cognizant that decisions and recommendations regarding therapies must be founded on evidence-based research directed at practical patient care in a cost-effective manner.
To write, edit, and publish this 1,000+-page text requires the dedication of all of the authors, as well as a professional publication staff to coordinate the technical aspects of editing and publishing. We, the authors and editors, acknowledge the following individuals at CMPMedica: Angela Cibuls, Project Manager; Susan Reckling, Managing Editor; Stacey Cuozzo, Production Editor; Andrew Barkus, Group Production Manager, Cara Glynn, Senior Editorial Director; and Beth Scholz, Group Vice President. We also thank Lisa Katz, Claudine Kiffer, Anne Landry, Andrew Nash, and Ronald Piana, for their efforts.
Richard Pazdur, MD
Director, Office of Oncology Drug Products
Center for Drug Evaluation and Research
US Food and Drug Administration
Lawrence D. Wagman, MD
Executive Medical Director
The Center for Cancer Prevention and Treatment
St. Joseph Hospital
Kevin A. Camphausen, MD
Chief, Radiation Oncology Branch
National Cancer Institute
William J. Hoskins, MD
Executive Director of Surgical Activities
Memorial Sloan-Kettering Cancer Center
New York, New York